The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 6, 2014, Pages 810-813

  Hoermann, G ^a   Gleixner, K V ^a   Dinu, G E ^b   Kundi, M ^c   Greiner, G ^a   Wimazal, F ^d   Hadzijusufovic, E ^a,e   Mitterbauer, G ^a   Mannhalter, C ^a   Valent, P ^a   Sperr, W R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF APPLIED SCIENCES WIENER NEUSTADT   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^e UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

allele burden; KIT D816V; mastocytosis; survival; treatment response

Indexed keywords

CLADRIBINE; HYDROXYUREA; INTERFERON; TRYPTASE; STEM CELL FACTOR RECEPTOR;

AGGRESSIVE SYSTEMIC MASTOCYTOSIS; ALLELE; ARTICLE; BLOOD; BONE MARROW; CELL INFILTRATION; CORRELATIONAL STUDY; CUTANEOUS MASTOCYTOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; HEMATOLOGIC DISEASE; HUMAN; INDOLENT SYSTEMIC MASTOCYTOSIS; MAJOR CLINICAL STUDY; MAST CELL; MAST CELL LEUKEMIA; MASTOCYTOSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SMOLDERING SYSTEMIC MASTOCYTOSIS; SURVIVAL; SYSTEMIC MASTOCYTOSIS; WORLD HEALTH ORGANIZATION; AMINO ACID SUBSTITUTION; GENETICS; MORTALITY; MUTATION;

ALLELES; AMINO ACID SUBSTITUTION; HUMANS; MASTOCYTOSIS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84899954282     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12409     Document Type: Article

References (15)

1. Longley BJ Jr, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999; 96: 1609-1614.
2. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995; 92: 10560-10564.
3. Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435-453.
4. Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O, et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 2013; 121: 2393-2401.
5. Kristensen T, Vestergaard H, Moller MB,. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn 2011; 13: 180-188.
6. Erben P, Schwaab J, Metzgeroth G, Horny HP, Jawhar M, Sotlar K, et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 2014; 93: 81-88.
7. Kristensen T, Vestergaard H, Bindslev-Jensen C, Moller MB, Broesby-Olsen S,. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol 2014; 89: 493-498.
8. Broesby-Olsen S, Kristensen T, Vestergaard H, Brixen K, Moller MB, Bindslev-Jensen C, et al. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis. J Allergy Clin Immunol 2013; 132: 723-728.
9. Kristensen T, Broesby-Olsen S, Vestergaard H, Bindslev-Jensen C, Moller MB,. KIT D816V mutation-positive cell fractions in lesional skin biopsies from adults with systemic mastocytosis. Dermatology 2013; 226: 233-237.
10. Kristensen T, Broesby-Olsen S, Vestergaard H, Bindslev-Jensen C, Moller MB, Mastocytosis Centre Odense University H. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis. Eur J Haematol 2012; 89: 42-46.
11. Kristensen T, Broesby-Olsen S, Vestergaard H, Bindslev-Jensen C, Moller MB, Mastocytosis Centre Odense University H. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis. Eur J Haematol 2013; 91: 106-111.
12. Sperr WR, Jordan JH, Fiegl M, Escribano L, Bellas C, Dirnhofer S, et al. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol 2002; 128: 136-141.
13. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD,. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 1999; 94: 2333-2342.
14. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108: 2366-2372.
15. Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013; 122: 2460-2466.